Charles Bennett to Quality of Life
This is a "connection" page, showing publications Charles Bennett has written about Quality of Life.
Connection Strength
1.835
-
Editorial comment. Urology. 2015 Feb; 85(2):413.
Score: 0.266
-
Editorial comment. Urology. 2013 Jul; 82(1):66.
Score: 0.236
-
Proxy assessment of health-related quality of life in african american and white respondents with prostate cancer: perspective matters. Med Care. 2009 Feb; 47(2):176-83.
Score: 0.176
-
Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004 Jun; 3(1):31-7.
Score: 0.127
-
Spouse ratings of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: an assessment of feasibility, reliability, and validity. Urology. 2001 Feb; 57(2):275-80.
Score: 0.101
-
Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments. Qual Life Res. 1999 Aug; 8(5):461-70.
Score: 0.091
-
A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res. 1999 May; 8(3):171-80.
Score: 0.089
-
Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures. J Urol. 1998 Nov; 160(5):1765-9.
Score: 0.086
-
Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998 Jul-Sep; 18(3):278-86.
Score: 0.084
-
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act. BMJ. 2016 Dec 30; 355:i6286.
Score: 0.076
-
Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers. Br J Cancer. 2014 Jul 29; 111(3):421-3.
Score: 0.064
-
Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec; 18(4):421-9.
Score: 0.060
-
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology. 2013 Jan; 81(1):130-4.
Score: 0.058
-
The blue cross blue shield assessment technology review: summary of findings. Best Pract Res Clin Haematol. 2005; 18(3):423-31.
Score: 0.033
-
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. Pharmacoeconomics. 2005; 23(8):767-75.
Score: 0.033
-
A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol. 2004 Apr; 93(1):164-9.
Score: 0.031
-
Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. Urology. 2003 Jan; 61(1):172-8.
Score: 0.029
-
QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology (Williston Park). 1999 Jun; 13(6):823-32; discussion 835-8.
Score: 0.022
-
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible? Cancer Invest. 1997; 15(3):227-36.
Score: 0.019
-
A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol. 1997; 32 Suppl 3:86-8.
Score: 0.019
-
Economic analyses in clinical trials for cooperative groups: operational considerations. Cancer Invest. 1997; 15(5):448-53.
Score: 0.019
-
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 01; 77(9):1854-61.
Score: 0.018
-
High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann Oncol. 2015 Jul; 26(7):1390-5.
Score: 0.017
-
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20; 32(30):3436-48.
Score: 0.016
-
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31.
Score: 0.015
-
Dermatologic challenges in cancer patients and survivors. Oncology (Williston Park). 2007 Nov; 21(12):1462-72; discussion 1473, 1476, 1481 passim.
Score: 0.010
-
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
Score: 0.009
-
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002 Jul 15; 95(2):361-76.
Score: 0.007
-
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 01; 19(5):1519-38.
Score: 0.006
-
Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000 Apr 04; 132(7):566-77.
Score: 0.006
-
Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000; 4(3):259-63;discussion 265.
Score: 0.006
-
Comparison of perspectives on prostate cancer: analyses of survey data. Urology. 1997 Sep; 50(3):366-72.
Score: 0.005